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We have constructed VSV recombinants lacking the viral glycoprotein gene and instead expressing rhesus macaque SIV receptors CD4 and
CCR5 with or without the receptor DC-SIGN. The recombinant expressing CD4 and CCR5 specifically infected SIV envelope protein-expressing
cells. Incorporation of DC-SIGN into the particles required deletion of the cytoplasmic domain. Inclusion of DC-SIGN in the particles definitely
enhanced infection, indicating that the enhancement by coexpression of DC-SIGN with CD4 and CCR5 does not require internalization of the
virus into cells. The recombinants also specifically infected, killed, and propagated in CEMx174 cells that were first infected with an SIV
expressing EGFP. If cells were superinfected with either of the recombinants after the primary SIV infection, the numbers of SIV-infected cells and
titers of infectious SIV in the cultures were significantly reduced. Such antivirals can now be tested in the SIV/non-human primate model for AIDS
to determine their therapeutic value in vivo.
D 2005 Elsevier Inc. All rights reserved.Keywords: DC-SIGN; CD4; CCR5; Virus targeting; VSVIntroduction
At the end of 2004, there were approximately 39 million
people worldwide infected with human immunodeficiency
virus (HIV) and about 4.9 million new infections occurred in
2004. HIV infection leading to acquired immunodeficiency
syndrome (AIDS) killed approximately 3.1 million people in
2004 (UNAIDS/WHO, 2004). Although highly active antire-
troviral therapy (HAART) is very effective (Yeni et al., 2004),
this is not generally available in the countries with the most
severe HIV/AIDS burdens. More effective and less costly
therapies are needed urgently.
Other anti-HIV-1 therapies have been extensively studied and
include ones that selectively target HIV-1-infected cells such as0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Box B-164, 4200 East 9th Ave., Denver, CO 80262, USA.immunotoxins (Berger et al., 1998; Pincus et al., 2003;
Saavedra-Lozano et al., 2004) and NK cells armed by a
recombinant Ig fusion protein (Gupta et al., 2005). Our
laboratory previously described a potential anti-HIV therapeutic
based on a recombinant vesicular stomatitis virus (VSV)
expressing the HIV receptor (CD4) and the HIV coreceptor
(CXCR4) in place of the VSV G attachment and fusion protein
(Schnell et al., 1997). The genes encoding these proteins were
expressed from the virus genome and the proteins were
incorporated into the viral envelope in place of VSV G. The
recombinant virus was able to bind to the HIV envelope (Env)
protein on the surface of HIV-infected cells and enter the cell
after virus–cell fusion catalyzed by the HIV Env protein on the
target cell. Once the potent VSV replicon was inside the cells, it
replicated to produce additional virus particles containing HIV
receptors, rapidly killed the HIV-infected cells, and greatly
reduced HIV titer in the culture. The effect on HIV replication in
culture persisted for at least 30 days. Other laboratories
described related studies using rabies virus and murine leukemia
virus (MuLV) pseudotyped with HIV-1 receptors CD4 and
CXCR4 (Mebatsion et al., 1997; Somia et al., 2000). These06) 86 – 97
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HIV-1-infected cells. However, the pseudotypes did not encode
the receptors and therefore could not provide long-term control
of HIV-1 infection.
A VSV recombinant expressing HIV receptors could
potentially function to reduce HIV load in humans by
specifically infecting, propagating in, and killing HIV-infected
cells. However, attempts to move this recombinant into human
therapeutic trials met with resistance from the U.S. Food and
Drug Administration because of the lack of an animal model
for testing the principle of such recombinant viruses. The
purpose of the present study was to develop a similar or
improved therapeutic that could be tested against simian
immunodeficiency virus (SIV) in a non-human primate model.
HIV-1 uses CD4 as a primary receptor and either CXCR4 or
CCR5 as a coreceptor (Alkhatib et al., 1996; Berson et al.,
1996; Deng et al., 1996; Doranz et al., 1996; Feng et al., 1996).
In rhesus macaques, SIV uses CD4 and CCR5 but does not
employ CXCR4 as a coreceptor (Chen et al., 1997; Edinger et
al., 1997; Marcon et al., 1997).
In addition to entry receptors, dendritic cell-specific ICAM-
3 grabbing nonintegrin (DC-SIGN) was identified as an
attachment receptor that can lead to HIV capture by cells,
internalization into cells, and transmission to T lymphocytes
(Geijtenbeek et al., 2000; Kwon et al., 2002). DC-SIGN has an
N-terminal cytoplasmic domain containing two internalization
motifs (YxxL and LL), a C-terminal extracellular domain
containing a lectin domain (a carbohydrate-recognition do-
main) and a stalk composed of a tandem repeat domain. DC-
SIGN can also enhance HIV/SIV infection in cis when
coexpressed with CD4 and the coreceptor (Lee et al., 2001;
Nobile et al., 2003). Rhesus macaque DC-SIGN (rDC-SIGN) is
closely related to human DC-SIGN and also has the ability to
capture HIV/SIV and transduce it to target cells (Baribaud et
al., 2001; Wu et al., 2002).
Vesicular stomatitis virus (VSV), a rhabdovirus, has a non-
segmented, negative-strand RNA genome that encodes five
structural proteins. Of these proteins, the glycoprotein (G) is the
only envelope protein. G protein attaches virus to a cell surface
receptor and, after endocytosis of the virus, catalyzes fusion
between virus and cell membranes at low pH. VSV infectsFig. 1. Gene orders in VSV recombinants expressing multiple SIV receptors. The ge
the VSV G gene) are illustrated. Rhesus macaque CD4 and CCR5 genes were inser
rhesus macaque DC-SIGN, or DC-SIGND35 with a deletion of sequences encoding 3
of the CCR5 gene in VSVDGrCC5 as indicated. The genes are transcribed from levirtually all animal cell types in culture, replicates exclusively in
the cytoplasm, produces abundant progeny virus, and rapidly
kills the infected cells. Our laboratory has developed methods
for recovering VSV from plasmid DNA copies and has
engineered the genome such that foreign genes can be inserted
and expressed in viruses recovered from the plasmid DNA
(Lawson et al., 1995; Schnell et al., 1996a, 1996b).
The potential HIV therapeutic engineered previously
(Schnell et al., 1997) expressed human CD4 and CXCR4
receptors in place of VSV G and controlled HIV replication
in culture. The goal of the present study was to develop a
recombinant VSV that would control SIV infection in vitro.
If successful, such a recombinant would then open the
possibility of testing of the therapeutic virus in a monkey
AIDS model. To achieve this aim, we have developed novel
VSVDG recombinants expressing multiple SIV receptors
from rhesus macaques. These viruses express rhesus ma-
caque CD4 (rCD4) and CCR5 (rCCR5) with or without
rhesus DC-SIGN (rDC-SIGN). The rDC-SIGN molecule was
introduced to enhance the VSVDG infection through
interaction of DC-SIGN with SIV Env protein. We show
here that the viruses could specifically target SIV Env-
expressing cells and that the infection was enhanced by the
presence of modified rDC-SIGN in the viral envelope. More
importantly, we show that these viruses efficiently infected
and killed SIV-infected cells and provided long-term control
of SIV infection in culture.
Results
Construction and recovery of VSV recombinants expressing
multiple SIV receptors
In the present study, we have generated VSV recombinants
expressing multiple SIV receptors for targeting of cells expres-
sing SIV Env protein. Initially, we constructed a VSVexpressing
rhesus macaque CD4 (rCD4) and CCR5 (rCCR5) genes. These
SIVreceptor genes were inserted between theM and L genes in a
plasmid construct (pVSVDG) from which the VSV G gene was
deleted (Fig. 1). The virus recovered from this construct was
designated VSVDGrCC5. Next, the gene encoding rhesusne orders in VSV recombinants including wild-type (wt) and VSVDG (lacking
ted between the M and L genes of VSVDG genome as indicated. Additionally,
5 N-terminal amino acids of the cytoplasmic domain, was inserted downstream
ft to right from the genome that is shown in the 3V–5V orientation.
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VSVDGrCC5 construct in an attempt to increase infectivity.
The virus recovered from this construct was designated
VSVDGrCC5D (Fig. 1). DC-SIGN, a C-type lectin, is a high
affinity receptor for attachment of HIV/SIV to cells and
enhances the virus entry when expressed along with CD4 and
coreceptor (Lee et al., 2001; Nobile et al., 2003). However, we
found that native rDC-SIGN expressed from the VSVDGrCC5D
construct was not incorporated into the VSV particles (see
below). Because our previous studies had shown that a
cytoplasmic domain from a foreign protein can inhibit its
incorporation into the VSV (Johnson et al., 1997, 1998; Owens
and Rose, 1993), we also generated a VSV expressing rDC-
SIGN with a deletion of 35 amino acids from its N-terminal
cytoplasmic domain (rDC-SIGND35). The virus recovered from
this construct was designated VSVDGrCC5DD35. Because of
deletion of the VSV G gene, the viruses were initially recovered
in the presence of complementing G protein and were
subsequently propagated in BHK cells expressing VSV G
protein (Schnell et al., 1997). Titers obtained were ¨5  106
PFU/ml.
Incorporation of CD4 and DC-SIGN into VSV particles
To determine if the SIV receptors were expressed from the
VSV recombinants and if they were incorporated into the virus
particles, we infected BHK-G cells with G-complemented
stocks of the viruses. Infected cells were labeled with
[35S]methionine and [35S]cysteine and viruses were purified
from the media after 18 h. Samples were split and digested with
PNGase F (which removes all N-linked glycans) or left
undigested. The proteins were then separated by SDS-PAGEFig. 2. Incorporation of SIV receptors into VSV particles. (A) 35S-labeled viruses. G
as VSV wild-type (wt) were initially grown in BHK-G cells after induction of G p
[35S]methionine and [35S]cysteine for 18 h. Viruses were then purified by ultracentrif
from virions were separated by SDS-PAGE and detected using a Molecular Dynami
in purified virions. Lysates were prepared from unlabeled, infected cells (a left pane
were detected using mouse anti-DC-SIGN antibody, followed by incubation with h
ECL system.to examine sizes of labeled proteins (Fig. 2A). VSV wild-type
(wt) showed the major bands L, G, N, P, and M proteins as
indicated. VSV G contains two N-linked glycans and, as
expected, migrated faster after digestion with PNGase F.
VSVDGrCC5, VSVDGrCC5D, and VSVDGrCC5DD35 lacked
G protein because G gene was deleted from their genomes and
production of G protein in BHK-G cells was probably shut-off
by their infection. The viruses instead contained a new protein
of the mobility expected for rCD4 (¨60 kDa) in addition to the
four VSV structural proteins. After digestion, rCD4 (which
contains three N-linked glycans) was expected to migrate
faster, coincident with the major bands of the N and P proteins.
We did not expect to detect the CCR5 and DC-SIGN proteins
in VSV particles without immunoblotting because of lower
expression levels and predicted comigration with N and P
proteins. We therefore next tried to detect rDC-SIGN molecules
in lysates of VSV-infected cells and in the VSV particles by
Western blot using anti-DC-SIGN antibody (Fig. 2B). The
proteins from lysates of cells infected with viruses and from
purified viruses were separated in SDS-PAGE and transferred
to a nitrocellulose membrane followed by detection with an
anti-DC-SIGN monoclonal antibody. Proteins with the pre-
dicted mobilities of rDC-SIGN and rDC-SIGND35 were
observed only in the extracts of cells infected with
VSVDGrCC5D and VSVDGrCC5DD35, respectively, and
not in the extracts of cells infected with VSV wt or
VSVDGrCC5. However, the native rDC-SIGN was not
incorporated into VSV particles while the rDC-SIGND35 with
a deletion in the cytoplasmic domain was incorporated into
particles. Our results indicate that the N-terminal cytoplasmic
tail of rDC-SIGN contains a sequence that interferes with its
incorporation into the VSV particles. A similar inhibitory-complemented VSVDGrCC5, VSVDGrCC5D, and VSVDGrCC5DD35 as well
rotein expression. After 4 h of infection, cells were labeled continuously with
ugation and incubated with or without PNGase F (+ or ). The labeled proteins
cs PhosphorImager. (B) AWestern blot of proteins in lysates of infected cells or
l) or purified viruses (a right panel), and applied for SDS-PAGE. The proteins
orseradish peroxidase-conjugated anti-mouse antibody, and visualized by using
Fig. 4. VSV recombinants expressing SIV receptors infect cells expressing SIV
envelope protein. 293T cells were transfected with a control plasmid or with
expression plasmids encoding SIVmac239 or 1A11 Env and Rev proteins. After
2 days, non-G-complemented VSVDG, VSVDGrCC5, or VSVDGrCC5DD35
was added to the cells. After 10 h, the cells were fixed and examined by
immunofluorescence microscopy using a mouse anti-VSV N protein antibody,
followed by FITC-conjugated anti-mouse antibody to detect VSV infection.
Panel A shows cells that were observed and photographed by using an Olympus
CK40 microscope. Panel B shows quantitation of N protein-positive cells from
several experiments. Titers of VSVDG (white bars), VSVDGrCC5 (gray bars), or
VSVDGrCC5DD35 (black bars) were calculated. The bars indicate mean plus
standard error.
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of the HIV Env protein (Johnson et al., 1998).
Because an antibody to rCCR5 was not available, we were
unable to confirm that it was incorporated into VSV particles.
However, subsequent functional studies indicate that it is
incorporated into the particles (see below).
Cell fusion mediated by SIV envelope proteins and multiple SIV
receptors expressed by VSVs
We reasoned that the SIVreceptor molecules expressed on the
surface of cells infected by the VSVrecombinants should be able
to mediate cell–cell fusion if the cells also expressed SIV Env
protein. To test this possibility, we infected SIV Env-expressing
cells with G-complemented VSVDGrCC5, VSVDGrCC5D, or
VSVDGrCC5DD35. To express SIV Env protein at the surface
of cells, we first infected BHK cells with a VSV recombinant
expressing SIVmac239 Env protein with its cytoplasmic tail
replaced with the VSV G cytoplasmic tail as well as G protein
(N. Rose, unpublished). After removing the inocula, the cells
were next infected with G-complemented VSVs expressing SIV
receptors or G-complemented VSVDG. Infection by the
VSVDGrCC5, VSVDGrCC5D, or VSVDGrCC5DD35 resulted
in cell fusion (syncytium formation) in cells expressing 239 Env
protein (Fig. 3). In contrast, infection with VSVDG comple-
mented with G did not cause fusion (Fig. 3). This result indicated
that functional SIV receptors were expressed by VSV recombi-
nants expressing two or three SIV receptors.
Specific infection of Env-expressing cells by VSVs bearing
multiple SIV receptors
Because the SIV receptors encoded by the VSVrecombinants
induced cell fusion in cells expressing SIV Env, next we wanted
to determine if the SIV receptors present on the surface of
VSVDG particles could mediate infection of cells expressing
SIV Env. To test this, we infected 239 or 1A11 Env-expressing
cells with non-complemented VSVDG, VSVDGrCC5, or
VSVDGrCC5DD35. After infection, the cells were fixed and
examined by immunofluorescence microscopy to detect infec-
tion by expression of VSV nucleocapsid (N) protein in the cells
(Fig. 4). VSVDG did not infect cells in the presence or absence
of SIV Env protein expression. In contrast, both VSVDGrCC5
and VSVDGrCC5DD35 specifically infected cells expressingFig. 3. Cell fusion induced by VSV recombinants expressing SIV receptors in cells e
plate were infected at 37 -C for 1 h with a VSV recombinant expressing both G prote
G cytoplasmic tail (moi 0.1). The cells were washed with serum-free DMEM and the
indicated (moi 0.01). They were observed by phase-contrast microscopy at 10–20
Photographs of the cells were taken at 10 h post-infection using a Nikon Diaphot mic
syncytia are indicated (arrows).SIVmac239 Env protein (Fig. 4A). The number of fluorescent
cells was counted, and the infectivity was quantified for cells
expressing either SIVmac239 or 1A11 Env (Fig. 4B). Infection
of 239 Env or 1A11 Env-expressing cells by the virus expressing
rDC-SIGND35 in addition to rCD4 and rCCR5was enhanced by
about two-fold compared to that by the virus expressing onlyxpressing SIV envelope protein. One million BHK cells in each well of a 6-well
in and SIVmac239 Env protein with its cytoplasmic tail replaced with the VSV
n infected with G-complemented VSVDG or VSVDG encoding SIV receptors as
h post-infection to determine if cell fusion was induced by the virus infection.
roscope with a 10 objective and a Nikon COOLPIX950 digital camera. Larger
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coreceptors rCCR5 and rDC-SIGND35 are all being incorpo-
rated into the VSV particles and that coexpression of rhesus DC-
SIGN with CD4 and CCR5 enhances infection without
internalization of the virus into cells.
Inhibition of infection by anti-DC-SIGN antibody or mannan
To examine further the involvement of rDC-SIGN in
mediating infection, we determined the effect of anti-DC-
SIGN antibody or mannan on infection of Env-expressing cells
by VSVDGrCC5 or VSVDGrCC5DD35. Both mannan and this
antibody are known to block binding of DC-SIGN to Env
protein and to inhibit SIV infection (Lee et al., 2001; Wu et al.,
2002). Non-complemented viruses were incubated with either
reagent, and then used to infect cells expressing SIV Env. After
infection, the cells were fixed and infectivity was examined by
immunofluorescence detecting VSV N protein expression (Fig.
5). Anti-DC-SIGN monoclonal antibody or mannan inhibited
VSVDGrCC5DD35 infection by about 50% or 70%, respec-
tively, but did not affect infection by VSVDGrCC5. This result
indicated that rDC-SIGND35 was present in the viral mem-
brane and involved in the enhancement of infection by
VSVDGrCC5DD35. The reagents did not completely block
the VSVDGrCC5DD35 infection, probably because DC-SIGN
is not essential for virus entry in CD4- and CCR5-dependent
manner.
Targeting of SIV-infected cells with VSVs encoding SIV
receptors
We next tested if VSVDGrCC5 and VSVDGrCC5DD35
could selectively target SIV-infected cells by interaction with
Env on the infected cell surface, and membrane fusion mediatedFig. 5. Anti-DC-SIGN or mannan inhibits infection by a VSV recombinant
expressing rDC-SIGND35. VSVDGrCC5 and VSVDGrCC5DD35 grown
without G complementation were incubated at 37 -C for 30 min with or
without 10 Ag/ml anti-DC-SIGN antibody or 100 Ag/ml mannan (Sigma-
Aldrich). These viruses were then added to 293T cells expressing SIVmac239
Env protein. After incubation for 10 h, the cells were fixed and examined by
immunofluorescence to detect VSV N protein. Positive cells were visualized by
fluorescence microscopy and counted. The shown data represent percentage
control by anti-DC-SIGN (gray bars) or mannan (black bars) calculated from
the numbers of positive cells on the treated vs. untreated cells (white bars). The
bars represent mean + standard error.by Env. We therefore infected CEMx174 cells with an SIV
recombinant encoding EGFP (Alexander et al., 1999) and 5 days
later, when approximately 10–20% of the cells were EGFP+, we
superinfected the cells with non-G-complemented VSVDG,
VSVDGrCC5, or VSVDGrCC5DD35. Two days later, the cells
were fixed and internally stained with anti-VSV N protein
antibody. The stained cells were then examined by fluorescence
microscopy for expression of EGFP or VSV N (Fig. 6).
CEMx174 cells were always present in clumps, as shown by
the bright-field images (left panels). All cultures inoculated with
SIV-EGFP showed a large fraction of cells expressing EGFP. In
cells infected with SIV-EGFP and then superinfected with
VSVDGrCC5 or VSVDGrCC5DD35, we observed VSV N
protein expression in a substantial fraction of the SIV-infected
(green) cells indicating that superinfection by the VSV
recombinants had occurred. A control experiment (Fig. 6)
showed that cells infected with SIV-EGFP and then super-
infected with VSVDG were not infected (no N protein
expression). This result indicates that the expression of SIV
receptors is required for superinfection. We also observed no
infection of non-SIV-infected CEMx174 cells by VSVDGrCC5
or VSVDGrCC5DD35 (data not shown).
Elimination of SIV-infected cells with VSVs expressing SIV
receptors
We previously demonstrated that a VSVDG recombinant
expressing CD4 and CXCR4 specifically infected, propagated
in, and killed HIV-1-infected cells, resulting in control of HIV-1
infection in culture. To determine if a similar effect could be
achieved with the recombinants expressing SIV receptors, we
carried out an extensive analysis, using flow cytometry, of the
effect of these viruses on the level of SIV infection. At 2 days
after SIV-EGFP infection, non-G-complemented VSVDGrCC5,
VSVDGrCC5DD35, or VSVDG (control) virus grown on BHK
cells was added to the infected cells. One control culture was
infected with SIV-EGFP only and another was left uninfected. A
fraction of the cells (10–20%) was harvested every 2 days, and
only live cells were analyzed for EGFP expression (SIV
infection) by flow cytometry. The infection was followed in
this manner for 40 days. Fig. 7A shows representative flow
cytometry data from one time point (day 20) in this experiment.
The majority of the live cells infected with SIV-EGFP alone or
SIV-EGFP followed by VSVDG were clearly SIV-infected by
day 20. In contrast, in cells superinfected with VSVDGrCC5 or
VSVDGrCC5DD35 on day two following the SIV-EGFP
infection, less than 5% of the cells were infected with SIV
(EGFP-positive).
A compilation of flow cytometry data obtained for 40 days
throughout this experiment is shown in Fig. 7B. After superin-
fection with VSVDGrCC5 or VSVDGrCC5DD35 on day two,
the percentage of EGFP+ cells increased to about 20% of the total
and then began to decrease rapidly and reached a plateau of less
than 5% by day 12 (Fig. 7B). In cells that were infected with SIV-
EGFP only, or superinfected with VSVDG, the percentage of
SIV-infected live cells continued to rise and reached a plateau
around 70–80% positive. In fact, the percentage of infected cells
Fig. 6. Targeting of SIV-infected cells by VSVDG recombinants expressing SIV receptors. CEMx174 cells were initially infected with SIVDnefEGFP encoding
EGFP gene. Five days later, the SIV-infected cells were infected by non-G-complemented VSVDG, VSVDGrCC5, or VSVDGrCC5DD35. Control cells were
infected with SIVDnefEGFP alone or left uninfected. Following infection for 2 more days, the cells were examined by immunofluorescence using mouse anti-VSV N
antibody and rhodamine-conjugated anti-mouse antibody. They were visualized and photographed to detect EGFP fluorescence (central panels) and VSV N protein
(right panels) expressed during SIV and VSV infection, respectively. Photographs show fluorescence images of the same fields and also bright-field images of the
same fields (left panels).
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as uninfected actually appeared to be expressing a low level of
EGFP (Fig. 7A). Our results demonstrate that both VSVDGrCC5
and VSVDGrCC5DD35 were able to control SIV-infected cells
and maintain this control at very low levels until at least 40 days
post-SIV infection. In other experiments, we have seen the same
level of control for 60 days (not shown). The VSVDGrCC5DD35
appeared slightly better than the VSVDGrCC5 at reducing the
number of SIV-infected cells, especially at later times when SIV-
infected cells were nearly undetectable in VSVDGrCC5DD35-
superinfected cultures.
Reduction of SIV titer by targeted VSV recombinants
The experiments described above indicated that the
VSVDGrCC5 or VSVDGrCC5DD35 recombinants were high-
ly effective at detecting and killing the SIV-infected cells. We
next wanted to determine the extent to which the superinfection
reduced SIV titer, since rapid killing of SIV-infected cells
would be expected to reduce SIV titer. In this experiment, SIV-
infected cells were superinfected with non-complemented
VSVDGrCC5 or VSVDGrCC5DD35 on day five after the
infection with SIV-EGFP. SIV titers were then determined from
the media at 5-day intervals for 30 days (Fig. 8). In control cells
infected with SIV alone, the SIV titers peaked at ¨105infectious particles/50 Al on day 10 post-SIV infection and
then fluctuated between about 103 and 104 infectious particles/
50 Al out to day 30. In contrast, in superinfected cells, there
was a decline in SIV titers from around 103 infectious particles/
50 Al on the day of superinfection down to about four
infectious particles/50 Al in the VSVDGrCC5-superinfected
cells at day 30, and to below detection in the
VSVDGrCC5DD35-superinfected cells at day 30. These data
are consistent with effective and rapid killing of SIV-EGFP-
infected cells by the VSV recombinants and significant
reduction of virus production.
Discussion
The purpose of the work described here was to determine if
we could generate a VSV recombinant that would specifically
target and kill cells infected with SIV. We constructed and
characterized novel VSVDG recombinants that express multi-
ple SIV receptors and incorporate them into the viral membrane
in place of the normal VSV G protein.
AVSVDG recombinant expressing rhesus macaque CD4 and
coreceptor CCR5 was able to infect cells expressing SIV Env
protein, but did not infect normal cells. The presence of human
DC-SIGN in addition to CD4 and coreceptor has been reported
to enhance HIV/SIV infection in cis by more than two-fold (Lee
Fig. 8. VSVDG recombinants expressing SIV receptors strongly suppress SIV
titers in coinfected cultures. SIVDnefEGFP-infected CEMx174 cells were
superinfected by non-complemented VSVDGrCC5 (open squares) o
VSVDGrCC5DD35 (closed squares) at day 5 post-SIV infection. Control cells
were infected with SIVInefEGFP only (open circles). Fifteen percent of each
culture supernatant was harvested on the indicated days to determine
SIVDnefEGFP titers. The supernatants were diluted serially and inoculated
onto fresh CEMx174 cells in 96-well plates. The plates were incubated for 7
days, and scored for the presence of EGFP-positive cells. The titers at each time
point were performed in triplicate. The dashed line shows the level of detection
of virus titer.
Fig. 7. Effective long-term control of SIV-infected cells after superinfection
with VSVDG recombinants expressing SIV receptors. At 2 days after infection
of CEMx174 cells with SIVDnefEGFP, the cells were infected by non-
complemented VSVDG, VSVDGrCC5, or VSVDGrCC5DD35. For controls,
other cells were infected with SIVDnefEGFP alone or left uninfected. The SIV
infection was followed for 40 days in this experiment. A fraction of the cells
(10–20%) were harvested every 2 days, and only live cells were analyzed by
flow cytometry to detect cells expressing EGFP. A representative histogram
from day 20 post-SIV infection is shown in panel A. Panel B shows a graph of
the percentage of SIVDnefEGFP-infected cells (EGFP+) included in the M1
population of panel A relative to the total number of live cells measured over
the entire 40-day experiment.
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encoding a modified rhesus macaque DC-SIGN protein and
found that incorporation of this DC-SIGN protein into virus
particles generated an about two-fold increase in infection of
cells expressing the SIV Env protein. Both recombinants were
able to target and kill SIV-infected cells in culture and they
reduced the number of SIV-infected cells and SIV titers by more
than 95% for at least 60 days in continuous culture. The
recombinant expressing all three SIV receptors reduced SIV titer
to below detection by day 30.
Interestingly, we found that the complete rDC-SIGN
expressed from the VSV recombinant was expressed at the cell
surface but was not incorporated into VSV particles. Although
many proteins expressed on the cell surface are incorporated
efficiently into VSV particles (Kretzschmar et al., 1997; Okuma
et al., 2003; Schnell et al., 1996a), we had found previously that
the HIV Env protein was an exception (Johnson et al., 1997;
Owens and Rose, 1993). HIV Env protein also did not colocalize
with VSV G protein to sites of VSV budding. However,truncation of the C-terminal cytoplasmic domain of HIV Env
resulted in colocalization at VSV budding sites on the plasma
membrane and incorporation into VSV particles. The signal in
HIV Env that blocked incorporation was mapped to a sequence
within the membrane-proximal 10 amino acids that contained a
YxxL internalization motif (Johnson et al., 1998). We noted that
the N-terminal cytoplasmic domain of rDC-SIGN also contained
a YxxL internalization motif as well as an LL internalization
motif (Wu et al., 2002). We therefore deleted 35 amino acids
(including both internalization motifs) from the N-terminal
cytoplasmic domain of rDC-SIGN and examined incorporation
of the rDC-SIGND35 protein into virus particles. We found that
this truncation allowed incorporation of the truncated protein
into VSV particles. Although the mechanism by which such
deletions allow incorporation of rDC-SIGN or HIV-1 Env into
VSV particles is not known, it probably involves elimination of
interactions that prevent the molecules from moving to sites on
the plasma membrane where VSV buds (Johnson et al., 1998).
More detailed mutagenic analysis will be required to determine
if the internalization motifs are involved in either case.
Little is understood about mechanisms through which DC-
SIGN enhances HIV/SIV infection of cells in trans and in cis.
Human DC-SIGN is at least thought to require internalization
of the virus captured by DC-SIGN into DCs for more efficient
trans-infection of CD4+ T cells (Kwon et al., 2002). However,
it is unknown whether internalization is needed for enhance-
ment of cis-infection when DC-SIGN is coexpressed with CD4
and the coreceptor. Rhesus DC-SIGN utilized in the present
study was truncated by deletion of the cytoplasmic domain
containing internalization motifs and incorporated into virus
membrane, thus indicating that employment of the cellular
internalization machinery is not essential for cis-infection
enhanced by rDC-SIGN.r
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virus titers on Env-expressing cells, we anticipated that the
VSV recombinant expressing modified rDC-SIGN might be
more efficient at killing SIV-infected cells in culture. However,
we found that the recombinants VSVDGrCC5 and
VSVDGrCC5DD35 both infected SIV-infected cells efficiently
and eliminated them at virtually identical rates. At 12 days
post-SIV infection (10 days post-superinfection), the percent-
age of SIV-infected cells was less than 5% of total live cells. In
contrast, SIV-infected cells were over 70% of the total in the
culture by day 12, when the cells were infected with SIV alone
or were mock-infected by a control DG virus. There appeared
to be somewhat better suppression of the SIV infection by
VSVDGrCC5DD35 between day 20 and 30 (Fig. 7) and
slightly better reduction of SIV titer in the culture at day 30
(Fig. 8), but these differences were not statistically significant.
Both viruses clearly suppressed SIV replication long-term, for
at least 2 months post-SIV infection.
In addition to measuring SIV titers in supernatants from the
coinfected cells, we also measured VSVDGrCC5 and
VSVDGrCC5DD35 titers at 20 days on 293T cells expressing
SIV Env. The titers ranged from 0.3–2.2  103 infectious
particles/ml, indicating that both VSVs continued to replicate
in SIV-infected cells and were present at titers similar to SIV
titers. It appears that the superinfection cannot eliminate SIV-
infected cells completely, probably because some SIV is
released from SIV-infected cells before the cells can be killed
by the VSVDG recombinants.
The viruses characterized in the present study will permit
future studies to determine if this strategy is effective in the
SIV-infected, rhesus macaque animal model. Animals with
relatively stable SIV loads as well as animals with high viral
loads and more rapid disease progression should be followed.
Also different modes of delivery of the virus will need to be
tested.
Our strategy has the major advantage that the antiviral agent
is itself replication-competent and thus may function as a self-
replicating ‘‘drug’’ that would remain present only as long as
there are SIV-infected cells present for it to replicate in.
Because the surface proteins of the recombinant virus are
exclusively host proteins, they should not induce virus-
neutralizing antibodies. Any cellular immune responses to the
VSV internal proteins that are generated might even enhance
elimination of VSV/SIV coinfected cells. This would of course
depend on effectiveness of the immune evasion tactics of SIV
such as downregulation of MHC class I molecule (Lock et al.,
1999; Swigut et al., 2004). Although mutations of SIV Env
protein accumulate rapidly, mutations that would generate
resistance to infection by the VSVDG viruses would presum-
ably be deleterious to SIV because they would eliminate
binding to its normal receptors.
Our study demonstrates that VSVDG recombinants expres-
sing two and three SIV receptors can possibly be even more
effective at controlling SIV infection than a recombinant
expressing two HIV receptors was at controlling HIV infection
(Schnell et al., 1997). They also have the major advantage of
being testable in a well-characterized animal model for AIDS.Materials and methods
Cells and virus
BHK-21 (BHK) cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 5% fetal bovine
serum (FBS), 100 Ag/ml streptomycin, and 100 units/ml
penicillin (5% FBS-DMEM). BHK-G cells (Schnell et al.,
1997) were cultured in DMEM containing 5% FBS, 750 Ag/ml
geneticin (G418), and 0.5 Ag/ml tetracycline. VSV G protein
expression was induced by transferring cells to tetracycline-
free medium approximately 18 h before infection. 293T cells
(Okuma et al., 2003) were grown in 10% FBS-DMEM on
collagen I-coated plates (Becton Dickinson). CEMx174 cells, a
human T and B cell hybrid line permissive for SIV infection
(Alexander et al., 1999), were cultured in RPMI1640 (Gibco)
containing 10% FBS (10% FBS-RPMI1640). All cells were
grown at 37 -C in 5% CO2.
SIVDnefEGFP (SIV-EGFP) is a virus derived from SIV-
mac239 that was engineered to express enhanced green
fluorescent protein (EGFP) by replacement of a part of its
nef gene with EGFP gene (Alexander et al., 1999). The virus
was propagated on CEMx174 cells in 10% FBS-RPMI1640,
and the levels of p27 gag protein were quantified using an SIV
core antigen kit (Coulter).
Construction of plasmids
Plasmid pVSVDG (Roberts et al., 1999) was used for
recovery of VSVDG. The following procedure was used to
construct a plasmid from which a recombinant VSV expressing
rhesus macaque CD4 and CCR5 genes in place of the VSV G
gene could be generated. The rhesus macaque CCR5 (rCCR5)
gene was amplified by PCR from an expression vector
pcDNA3-rCCR5 (Puffer et al., 2002) (kindly provided by Dr.
R. Doms) using Vent polymerase (New England Biolabs). The
forward primer was 5V-GGGGCTCGAGAAGATGGATTAT-
CAAGTGTCAA GT-3V. This primer contained an XhoI site
(bold) for further cloning. The reverse primer was 5V-
AATTGCTAGCTTGCGGCCGCTTAACCTAGGTCA-
CAAGCCC ACAGATATTTC-3V. This primer contained NheI,
NotI, and AvrII sites (bold) for further cloning. This product
was excised with XhoI and NheI, and ligated into pVSV-XN2
(Schnell et al., 1996b) that had been digested with the same
enzymes, yielding pVSV-rCCR5. A DNA encoding rhesus
macaque CD4 (rCD4) was obtained from rhesus peripheral
blood mononuclear cell RNA by RT-PCR using an oligo(dT)15
primer in RT followed by PCR with forward primer 5V-CCG
GGTACCACGCGTACAATGAACCGGGGAGTCCCTTT-
TAG-3V and reverse primer 5V-GGGCCCCTCGAGCGTGA-
TATCTGTTAGTTTTTTTCATACTCAAA TGGGGCTA-
CATGTCTTC-3V. The forward primer contained KpnI (bold)
and MluI sites (bold and underlined). The reverse primer
contained an XhoI site (bold) and a VSV transcription stop-
start signal (underlined). The PCR product was digested with
KpnI and XhoI, and ligated into the same sites in pBluescript to
generate pBS-rCD4. The rCD4 and G genes were excised from
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XhoI. The rCD4 gene was cloned into the G-deleted pVSV-
rCCR5 vector, yielding pVSVDGrCC5, a plasmid containing
the rCD4 and rCCR5 genes and lacking the VSV G gene.
To add the rhesus macaque DC-SIGN (rDC-SIGN) gene to
this plasmid, rDC-SIGN was amplified by PCR from
pcDNA3.1-mac-DC-SIGN (kindly provided by Dr. V. Kewal-
Ramani). The forward primer was 5V-GATCGGGCCCCC-
TAGGTA TGAAAAAAACTAACAGTAATCAAAATGAGT-
GACTCCAAGGAACCAAG-3V. This primer contained an
AvrII site (bold) and a VSV transcription stop-start signal
(underlined). The reverse primer was 5V-GTTAGGGA-
TAGGCTTACCTTCGAAC-3V. This product was digested
with AvrII and NotI, and inserted into pVSVDGrCC5 that
had been digested with the same enzymes to yield a plasmid
designated pVSVDGrCC5D. This plasmid was used to recover
a VSVDG recombinant expressing rhesus CD4, CCR5, and
DC-SIGN.
Because we found that the full-length rDC-SIGN was not
incorporated into VSV particles, we also generated a truncated
rDC-SIGN (rDC-SIGND35) gene, encoding rDC-SIGN in
which 35 N-terminal amino acids (amino acids 2–36) of the
cytoplasmic domain were deleted. This gene was amplified from
pcDNA3.1-mac-DC-SIGN by PCR. The forward primer was 5V-
GATCGGGCCCCCTAGGTATGAAAAAAACTAACAG-
TAATCAAAATGTGTCTTGGCCATGGCCCCCTGGTCC-3V.
This primer contained an AvrII site (bold) for further cloning
and a VSV transcription stop-start signal (underlined). The
reverse primer was the same as that used to amplify the
complete rDC-SIGN gene. The PCR product was digested with
AvrII and NotI, and then rDC-SIGND35 gene was ligated into
pVSVDGrCC5 that had been digested with the same enzymes.
This plasmid was designated pVSVDGrCC5DD35 and was
used to recover VSV expressing rhesus CD4, CCR5, and the
deleted form of DC-SIGN.
Recoveries of VSV recombinants
VSVs expressing SIV receptors were recovered from
pVSVDGrCC5, pVSVDGrCC5D, and pVSVDGrCC5DD35
by established methods (Lawson et al., 1995; Schnell et al.,
1997). BHK cells were plated to approximately 50% confluency
on 10-cm-diameter dishes. The cells were then infected at a
multiplicity of infection (moi) of 10 with vTF7-3, a recombinant
vaccinia virus that expresses T7 RNA polymerase (Fuerst et al.,
1986). After 1 h, each dish of cells was transfected with 3 Ag of
pBS-N, 5 Ag of pBS-P, 1 Ag of pBS-L, 4 Ag of pBS-G, and 10 Ag
of pVSVDGrCC5, pVSVDGrCC5D, or pVSVDGrCC5DD35
using a cationic liposome reagent (Rose et al., 1991). The cells
were then incubated at 37 -C for 48 h. Cell supernatants were
passed through a 0.2-Am-pore-size filter to remove the majority
of the vaccinia virus, and then applied to fresh BHK-G cells
previously induced to express G protein (Schnell et al., 1997).
The cells were incubated for an additional 48 h at 37 -C.
Recovery of infectious viruses was confirmed by scanning the
BHK-G cell monolayers for VSV cytopathic effect. Individual
plaques were isolated from cell monolayers infected with thesupernatants, and grown on BHK-G cells expressing induced
VSV G protein. Viral supernatants were passed three times
through a 0.1-Am-pore-size filter to remove residual vaccinia
virus completely. Such G-complemented stocks were then
harvested and clarified by low-speed centrifugation to remove
cell debris. All supernatants containing viruses were stored at
80 -C until use. VSVDG was recovered from pVSVDG as
described previously (Roberts et al., 1999).
Preparation of non-G-complemented DG viral stocks
For preparation of DG viral stocks that were not comple-
mented with VSV G, G-complemented stocks were used to
infect 80% confluent BHK cells at an moi of approximately 1.
After adsorption at 37 -C for 2–3 h, the inocula were removed
and cells were washed twice with DMEM to remove input, G-
complemented viruses. The cells were then incubated in fresh
10% FBS-DMEM at 37 -C for 24 h. The next day, media
containing DG viruses were collected, clarified by centrifuga-
tion, and viral supernatants were stored at 80 -C. The DG
viruses were incubated with anti-VSV G neutralizing anti-
bodies I1 and I14 (at 1:200 dilution of each) at 37 -C for 30
min immediately before inoculation to inactivate infection by
residual G.
Metabolic labeling and analysis of purified viruses
BHK-G cells expressing VSV G protein (106/well on a 6-
well plate) were infected with VSV wt or G-complemented
VSVDG expressing SIV receptors (moi ¨1). After 4 h at 37 -C,
the cells were rinsed twice with methionine- and cysteine-free
DMEM and then incubated overnight at 37 -C with methionine-
and cysteine-free DMEM containing 100 ACi of [35S]methio-
nine and [35S]cysteine (Perkin Elmer). The following day,
supernatants were harvested, centrifuged at 1, 250g for 5 min,
and viruses were purified twice by ultracentrifugation at
120,000  g through a 20% sucrose solution containing 10
mM Tris–HCl (pH 7.4) and 1 mM EDTA. Virus pellets were
resuspended in a glycoprotein denaturing buffer (0.5% sodium
dodecyl sulfate [SDS], 1% h-mercaptoethanol) containing 0.05
M sodium phosphate and 1% Nonidet P-40, and incubated with
or without PNGase F (New England Biolabs) at 37 -C for 10 h.
Then, the proteins were separated by electrophoresis on a
sodium dodecyl sulfate-10% polyacrylamide gel (SDS-PAGE),
and were detected by using a PhosphorImager (Molecular
Dynamics).
Western blot
BHK or BHK-G cells expressing VSV G protein (¨80%
confluent) were infected with VSV wt, G-complemented
VSVDGrCC5, VSVDGrCC5D, or VSVDGrCC5DD35 (moi
¨1). Cell extracts were prepared from the infected cells at 16
h post-infection. The cells were rinsed twice with phosphate-
buffered saline (PBS) and lysed in 0.5 ml of detergent solution
(1% Nonidet P-40, 0.4% deoxycholate, 10 mM Tris–HCl [pH
7.4], 66 mM EDTA). The cell lysates were collected and
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stored at 80 -C.
At 1–2 days post-infection, viruses were purified by
ultracentrifugation through a sucrose solution as described
above. Virus pellets were resuspended in sample buffer (62.5
mM Tris–HCl [pH 6.8], 10% glycerol, 2% SDS, 0.1% h-
mercaptoethanol) and stored at 80 -C until use. The cell
extracts and purified viruses above were electrophoresed on an
SDS-10% polyacrylamide gel. The separated proteins were
transferred to a nitrocellulose membrane using a Mighty Small
(Hoefer Pharmacia Biotech) apparatus. The membrane was
blocked with 5% low fat milk powder in TBST (20 mM Tris–
HCl [pH 7.5], 150 mM NaCl, 0.1% Tween 20) for 1 h at room
temperature and then incubated with a 1:1000 dilution of a
monoclonal antibody to human DC-SIGN (mouse IgG, R&D
systems) for 1 h at room temperature, followed by incubation
with a 1:10,000 dilution of horseradish peroxidase-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch) for 1 h at
room temperature. After washing by TBST, the proteins were
visualized using enhanced chemiluminescence (ECL, Amer-
sham Biosciences) system.
Titration of VSV recombinants
G-complemented VSV stocks were diluted serially in FBS-
free DMEM, and the diluted samples were inoculated onto
BHK-G cells expressing G protein (¨1  106/well). After
adsorption of the viruses for 30 min, medium containing 1%
methylcellulose was added to each well. Numbers of plaques
were counted after 2–3 days to determine titers.
For titration of non-G-complemented VSVs, viruses were
incubated with neutralizing anti-VSV G monoclonal antibodies
I1 and I14 (1:200 antibody dilution). Then, 293T cells that had
been transfected for 2 days with both an expression plasmid
pcDNA3 for SIV Env protein (Puffer et al., 2002) (generously
provided by Dr. R. Doms) and pcRev (Sutton and Littman,
1996) (kindly provided by Dr. R. Sutton) using LipofectAmine
Plus (Invitrogen) were infected with the non-complemented
viruses. After 10 h incubation, the cells were fixed and
examined by immunofluorescence to detect expression of
VSV N protein as a measure of VSV infection. The cells were
observed and numbers of cells expressing VSV N protein were
counted by fluorescence microscopy. Titers of non-comple-
mented VSVs were calculated as infectious particles per ml.
Indirect immunofluorescence
To determine if non-complemented VSVDG viruses infected
cells expressing SIV Env protein at the surface, ¨1  106 293T
cells were seeded on each well of a 6-well plate. The cells were
transfected by lipofection with pcDNA3 carrying SIVmac239
Env or 1A11 Env and pcRev. At 48 h post-transfection, VSVDG
viruses including both I1 and I14 were inoculated to the cells
expressing SIV Env protein. After 10 h, the cells were fixed in
3% paraformaldehyde, washed in PBS containing 10 mM
glycine (PBS-Glycine), and permeabilized with 1% Triton X-
100 in PBS-Glycine. Then, the cells were incubated in a 1:100dilution of anti-VSV N antibody at 37 -C for 10 min, followed
by a 1:100 dilution of a fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse antibody (Jackson ImmunoRe-
search) at 37 -C for 10 min. The cells were photographed with
an Olympus C-3040Zoom digital camera on an Olympus CK40
microscope.
To determine if non-complemented VSVDG viruses specif-
ically infected SIV-infected cells, at 5 days after infection of
CEMx174 cells by SIVDnefEGFP, VSVDGs including anti-G
antibodies were inoculated to the cells. A portion of cells were
harvested from each culture at 7 days post-SIV infection, fixed
with Cytofix/Cytoperm (BD Biosciences) overnight, and
washed by PBS. After permeabilization with 1% Triton X-
100, the cells were incubated with anti-VSV N antibody diluted
at 1:100 at 37 -C for 10 min and followed by rhodamine-
conjugated goat anti-mouse antibody (Jackson ImmunoRe-
search) at 37 -C for 10 min. Washed cells were observed by
fluorescence microscopy to visualize EGFP expression or VSV
N protein expression. Cells were photographed with a SPOT
digital camera using a Nikon Microphot-FX microscope
equipped with a 25 objective.
Infection by VSV after SIV infection and flow cytometry
analysis
CEMx174 cells (5  105) were seeded on each well of a 24-
well plate, and an SIVDnefEGFP stock containing 10 ng p27
gag was inoculated to each well. At 2 or 5 days post-SIV
infection, the SIV-infected cells were superinfected with 0.8 
104 infectious particles of VSVDGs expressing SIV receptors
or an amount of VSVDG that was produced from the same
number of BHK cells. The viruses were non-G-complemented
and incubated with anti-G antibodies before inoculation. The
SIV infection was followed for 40–60 days. A portion of cells
(10–20%) was collected from each culture well every other
day and the same amounts of fresh medium were added back.
The harvested cells were then fixed with Cytofix/Cytoperm at 4
-C overnight, washed by PBS, and only live cells were
analyzed by flow cytometry to detect EGFP-positive cells.
Percentages of positive cells included in the M1 population
were calculated from total numbers of collected live cells.
Determination of SIV titers
Supernatants from infected cultures were harvested every
fifth day and serially diluted 3-fold. Fifty thousand CEMx174
cells were added to each well of 96-well plates and infected with
the serial dilutions. Titration at each time point was performed in
triplicate. The plates were incubated at 37 -C for 7 days and
scored for the presence of EGFP+ cells. Titers were calculated as
described previously (Schnell et al., 1997) and are reported as
50% tissue culture infectious doses (TCID50) per 50 Al.
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